Propionibacterium acnes Specific Neutra™ Antibody Products

Are prolonged timelines in antibiotic development or inconsistent results in targeting Propionibacterium acnes undermining your research? Creative Biolabs' P. acnes specific Neutra™ antibody products leverage advanced hybridoma screening and epitope-specific engineering to deliver highly specific, cross-reactive antibodies, enabling robust detection and neutralization of P. acnes in complex biological systems.

Introduction to P. acnes

Propionibacterium acnes (P. acnes), a Gram-positive, anaerobic bacterium, resides predominantly in sebaceous-rich regions of human skin and mucosal surfaces. It thrives in lipid-rich microenvironments, metabolizing triglycerides into pro-inflammatory fatty acids. While a commensal organism, P. acnes is implicated in pathogenic states, including acne vulgaris, prosthetic joint infections, and chronic inflammatory disorders. Its dual role as both a skin microbiota member and opportunistic pathogen underscores the complexity of targeting it effectively.

• Structure

P. acnes possesses a multilayered cell wall enriched with peptidoglycan and lipoteichoic acids, which mediate host cell adhesion and immune evasion. Surface-exposed proteins, such as CAMP factor 1 (a pore-forming toxin) and dermatan sulfate adhesins, are critical for virulence. The bacterium's extracellular polysaccharide capsule, variable across strains, enhances biofilm formation and resistance to phagocytosis. Recent structural studies using cryo-electron tomography reveal dynamic membrane remodeling during host cell invasion, highlighting potential therapeutic targets.

• Related Signaling Pathways

P. acnes activates innate immune responses via Toll-like receptor 2 (TLR2) and nucleotide-binding oligomerization domain (NOD)-like receptors, triggering NF-κB and MAPK pathways to upregulate pro-inflammatory cytokines (IL-1β, IL-6, TNF-α). The CAMP factor synergizes with host secretory phospholipase A2 to amplify inflammasome activation, exacerbating tissue damage. Additionally, P. acnes-derived porphyrins induce reactive oxygen species (ROS) through photoactivation, perpetuating oxidative stress in acne lesions. Targeting these pathways requires antibodies capable of neutralizing both bacterial components and downstream inflammatory cascades.

Fig.1 Inhibition of P. acnes-induced skin inflammation.¹

• Related Diseases

P. acnes is the primary etiological agent in acne vulgaris, affecting over 85% of adolescents and adults globally. Beyond cutaneous disease, it causes invasive infections such as prosthetic joint implant-associated osteomyelitis, endophthalmitis, and sarcoidosis-like systemic inflammation. Its biofilm-forming capability complicates treatment, fostering antibiotic resistance and chronic recurrence.

Applications of P. acnes Neutralizing Antibodies

• Pathogenic Mechanisms and Diagnostic Innovations

Anti-P. acnes antibodies enable precise detection of bacterial load and biofilm formation in clinical samples. In acne research, they quantify CAMP factor expression in sebum samples, correlating with disease severity. For implant-associated infections, these antibodies identify bacterial colonization on prosthetic surfaces via fluorescence-labeled probes, aiding early diagnosis.

• Therapeutic Intervention and Vaccine Development

Neutralizing monoclonal antibodies targeting CAMP factor 1 reduce inflammation in murine acne models by 70%, outperforming traditional retinoids. In biofilm-disruption studies, anti-adhesin antibodies enhance antibiotic penetration, lowering minimal inhibitory concentrations (MICs) by 50%. Preclinical vaccine candidates conjugated with P. acnes surface proteins elicit opsonic antibodies, reducing bacterial burden in primate models.

• Host-Microbe Interaction Studies

Antibodies against P. acnes TLR2 ligands dissect host-pathogen crosstalk in ex vivo skin explants. Flow cytometry panels incorporating these antibodies profile macrophage polarization states in response to bacterial challenge, identifying novel checkpoints for immunomodulatory therapies.

Our Anti-P. acnes Antibodies

Creative Biolabs' anti-P. acnes antibodies target conserved virulence factors, including CAMP factor 1, surface adhesins, and biofilm matrix proteins. These antibodies are rigorously validated for:

- Specificity: No cross-reactivity with commensal skin flora (e.g., Staphylococcus epidermidis).

- Functionality: Neutralize toxin activity and block bacterial adherence in vitro and in vivo.

- Versatility: Compatible with ELISA, IHC, flow cytometry, and functional neutralization assays.

Developed using phage display libraries and affinity maturation, these antibodies exhibit sub-nanomolar binding affinity, ensuring reliable performance in translational research and diagnostic development.

Creative Biolabs' P. acnes specific Neutra™ antibody products empower researchers to unravel bacterial pathogenesis and accelerate therapeutic breakthroughs. With industry-leading specificity and validation across diverse applications, our antibodies are indispensable for academia and biopharma.

Contact our team today to explore customized solutions for your P. acnes research project.

REFERENCE

1. Nguyen, Cuong Thach, et al. "Inhibitory effects of superoxide dismutase 3 on Propionibacterium acnes-induced skin inflammation." Scientific Reports 8.1 (2018): 4024. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.1038/s41598-018-22132-z